drugset / Trial / NCT04290871

Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.

NCT04290871

Phase 2 Withdrawn Xijing Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

The investigators will enroll 104 patients with severe COVID-19 infection that mechanical ventilation is needed for respiratory support. Patients will be randomized to receive either inhaled nitric oxide (per protocol) or a placebo. ICU Standards of care will be the institution's own protocols (such as ventilation strategies and use and dose of antivirals and antimicrobials, steroids, inotropic and vasopressor agents).

Timeline

Start
2023-01-16
Primary completion
2023-12-31
Completion
2024-04-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 80 ppm Inhaled